Joey Bose blends a rare mix of biomedical training, Wall Street execution, and early-stage biotech operations. Trained as a cancer biologist at the University of Virginia and Johns Hopkins, he began his career in academic research before moving into biotech investment banking, where he advised emerging life sciences companies on capital strategy, financings, and M&A. The experience gave him a front-row seat to an industry dominated by gatekeepers, misaligned incentives, and capital-first thinking.

In 2018, Joey stepped into Cytonics at a moment of existential risk and led a full turnaround of the Company. With no access to traditional venture capital or pharma partnerships, he pioneered the use of Equity Crowdfunding as a primary capital formation strategy in biotech, an approach that, at the time, was largely dismissed by the industry. Since then, he has raised over $25 million from 7,000+ individual investors, advanced Cytonics from preclinical-stage into first-in-human clinical trials and established a new precedent for how capital-intensive therapeutics companies can be built outside the VC-pharma ecosystem. Under his leadership, Cytonics has become a proof point that disciplined execution, regulatory rigor, and aligned incentives can outperform convention.

Dr. Gaetano Scuderi is a Stanford-trained spine surgeon and early pioneer of orthobiologics who has spent decades working at the intersection of orthopedic surgery and molecular medicine. His work is rooted in a contrarian belief: degenerative disease should be treated by restoring biology, not replacing anatomy. That philosophy led him to study alpha-2-macroglobulin (A2M), a naturally occurring protease inhibitor capable of slowing cartilage degradation at its source, and to invent APIC (Autologous Protease Inhibitor Concentrate), a device-based therapy that has been used in more than 10,000 patients, including professional athletes.

In 2006, Dr. Scuderi founded Cytonics to pursue a more ambitious goal: engineering a recombinant, scalable biologic version of A2M suitable for global clinical development, giving rise to CYT-108. A 5th-degree black belt in Brazilian Jiu-Jitsu, he brings the same discipline, patience, and strategic thinking to biotech, where success is less about brute force and more about long-term positioning. He often compares drug development to a high-stakes chess match, where winning depends on anticipating moves ahead and executing with precision.

Michael Hartwich leads creative development and digital advertising at Cytonics, where he is responsible for shaping how the company communicates its science, strategy, and long-term vision to investors and the broader public. His role focuses on translating complex biology into clear, disciplined narratives that build credibility, understanding, and alignment over time.

With a career focused on visual storytelling and digital strategy, Michael has worked extensively with early-stage and growth-stage companies operating in highly regulated, capital-intensive industries. At Cytonics, he oversees brand development, campaign strategy, and digital advertising efforts that support capital formation and investor education while maintaining scientific and regulatory integrity.

Michael’s approach is grounded in the belief that in biotechnology, communication is part of execution. Clear storytelling is not about persuasion, but precision. By respecting the science and the audience equally, he helps ensure that Cytonics’ message remains durable under scrutiny and aligned with the company’s long-term objectives.